相关实验视频
Updated: Jun 25, 2025

15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
9.6K
更新关于最近在肌缩侧面硬化症的进展
Nilo Riva1, Teuta Domi2, Laura Pozzi2
13Rd Neurology Unit and Motor Neuron Disease Centre, Fondazione IRCCS "Carlo Besta" Neurological Insitute, Milan, Italy. nilo.riva@istituto-besta.it.
Journal of neurology
|May 27, 2024
概括
在了解肌缩性侧面硬化症 (ALS) 分子机制方面的最新进展正在为基因疗法铺平道路. 新的辅助技术增强了ALS患者的个性化护理,改善了整体管理.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 临床医学 临床医学
背景情况:
- 在了解肌缩侧面硬化症 (ALS) 的分子基础方面取得了重大进展.
- 新兴的基因治疗策略提供了新的治疗途径.
- 辅助技术的进步使得个性化的支持和症状护理成为可能.
研究的目的:
- 为最近的ALS研究提供全面的更新.
- 为了突出最新的临床试验结果.
- 概述ALS患者管理的未来方向.
主要方法:
- 关于ALS病变的最新科学文献的综述.
- 对当前临床试验数据的分析.
- 综合多学科ALS护理新兴趋势.
主要成果:
- 增强对ALS分子机制的理解.
- 研究结果的早期转化为临床实践,包括基因疗法.
- 通过辅助技术改善个性化护理.
结论:
- 分子洞察力和技术进步的整合正在改变ALS管理.
- 未来的研究应该专注于改进基因疗法和优化多学科护理策略.
- 持续的进展有望改善ALS患者的治疗结果和生活质量.
相关概念视频
Parkinson's Disease: Overview
528
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
528
Alzheimer's Disease: Overview
465
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465
Cross-bridge Cycle
117.3K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
117.3K
Alzheimer's Disease: Treatment
180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K

